

Special Issue

Novel and Multidimensional Technologies to Accelerate Vaccine Development

Message from the Guest Editors

While recent technological advancements in vaccine development have enhanced our ability to combat infectious diseases, novel and multidimensional approaches are needed to reduce disease burden, reduce development timelines for vaccine candidates, and ensure public safety. This Special Issue will highlight recent advancements in the field (e.g., cost savings, reduced dosage, enhanced candidate selection, improved analytics, clinical trial design and execution, higher volume/purity manufacturing systems) for both known (e.g., influenza, RSV, malaria) and novel (e.g. Zika, SARS, COVID-19) pathogens. We encourage authors from all sectors of vaccine development, manufacturing, and administration to submit their recent findings to expand our collective knowledge and aid in the development of these life-saving therapies.

Guest Editors

Dr. John M. Hickey

Scientific Assistant Director, Vaccine Analytics and Formulation Center (VAFC), University of Kansas, 1450 Jayhawk Blvd, Lawrence, KS 66045, USA

Dr. Jayant Arora

Institution of Regeneron Pharmaceuticals, Tarrytown, NY, USA

Deadline for manuscript submissions

closed (31 January 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/45817

Vaccines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).